Quality of life in survivors of hematological malignancies stratified by cancer type, time since diagnosis and stem cell transplantation.

摘要: OBJECTIVES Quality of life (QoL) has become an important tool to guide decision making in oncology. Given the heterogeneity among hematological cancer survivors, however, clinicians need comparative data across different subsets. METHODS This study recruited survivors malignancies (≥2.5 years after diagnosis) from 2 German registries. QoL was assessed with EORTC QLQ-C30. The sample stratified by type, time since diagnosis, treatment stem cell transplantation (SCT) and type SCT. First, levels were compared subsamples when controlling for several covariates. Second, we contrasted gender- age-matched population controls obtained general population. RESULTS Of 2001 contacted mail, 922 (46%) participated study. did not significantly differ between subsamples. All scored lower functioning higher symptom burden (all P < .001). Almost all these group effects reached clinically meaningful sizes (Cohen's d ≥ .5). Group differences global health/QoL mostly non-significant. CONCLUSIONS Hematological are associated practically relevant impairments irrespective central medical characteristics. Nevertheless, seem evaluate their overall situation as relatively well.